A Phase 1b Study of LY2835219 in Combination With Multiple Single Agent Options for Patients With Stage IV NSCLC
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 09 Mar 2018
At a glance
- Drugs Abemaciclib (Primary) ; Gemcitabine (Primary) ; LY 3023414 (Primary) ; Pembrolizumab (Primary) ; Pemetrexed (Primary) ; Ramucirumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms KEYNOTE-238
- Sponsors Eli Lilly
- 05 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 04 Dec 2017 Planned End Date changed from 1 Jun 2018 to 1 Nov 2018.
- 04 Dec 2017 Planned primary completion date changed from 1 Jun 2018 to 1 May 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History